Status:
COMPLETED
Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects
Lead Sponsor:
Ascletis Pharmaceuticals Co., Ltd.
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to evaluate the effects of itraconazole (a strong inhibitor of cytochrome P450 3A (CYP3A)) and rifampicin (a strong inducer of CYP3A) on the pharmacokinetics of ...
Eligibility Criteria
Inclusion
- Key
- 19kg/m2 ≤ BMI \<40kg/m2.
- Key
Exclusion
- History of, or current digestive system, nervous system disease, etc..
- Taking drugs or foods that inhibit or induce the liver's metabolism.
Key Trial Info
Start Date :
April 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 14 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04843449
Start Date
April 4 2021
End Date
May 14 2021
Last Update
August 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hunan provincial people's hospital
Changsha, Hunan, China